313 related articles for article (PubMed ID: 18020921)
1. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
Anderson P; Nuñez R
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
[TBL] [Abstract][Full Text] [Related]
2. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
Anderson PM; Wiseman GA; Dispenzieri A; Arndt CA; Hartmann LC; Smithson WA; Mullan BP; Bruland OS
J Clin Oncol; 2002 Jan; 20(1):189-96. PubMed ID: 11773169
[TBL] [Abstract][Full Text] [Related]
3. Samarium for osteoblastic bone metastases and osteosarcoma.
Anderson P
Expert Opin Pharmacother; 2006 Aug; 7(11):1475-86. PubMed ID: 16859431
[TBL] [Abstract][Full Text] [Related]
4. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours.
Milner RJ; Dormehl I; Louw WK; Croft S
J S Afr Vet Assoc; 1998 Mar; 69(1):12-7. PubMed ID: 9646255
[TBL] [Abstract][Full Text] [Related]
5. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223.
Anderson PM; Subbiah V; Rohren E
Adv Exp Med Biol; 2014; 804():291-304. PubMed ID: 24924181
[TBL] [Abstract][Full Text] [Related]
6. Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP.
Bianchi L; Baroli A; Marzoli L; Verusio C; Chiesa C; Pozzi L
Eur J Nucl Med Mol Imaging; 2009 Jan; 36(1):122-9. PubMed ID: 18751975
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer.
Dolezal J; Vizda J; Odrazka K
Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733
[TBL] [Abstract][Full Text] [Related]
8. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.
Serafini AN
Q J Nucl Med; 2001 Mar; 45(1):91-9. PubMed ID: 11456381
[TBL] [Abstract][Full Text] [Related]
9. High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.
Franzius C; Bielack S; Sciuk J; Vollet B; Jürgens H; Schober O
Nuklearmedizin; 1999; 38(8):337-40. PubMed ID: 10615669
[TBL] [Abstract][Full Text] [Related]
10. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases.
Resche I; Chatal JF; Pecking A; Ell P; Duchesne G; Rubens R; Fogelman I; Houston S; Fauser A; Fischer M; Wilkins D
Eur J Cancer; 1997 Sep; 33(10):1583-91. PubMed ID: 9389919
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
Turner JH; Claringbold PG; Hetherington EL; Sorby P; Martindale AA
J Clin Oncol; 1989 Dec; 7(12):1926-31. PubMed ID: 2585026
[TBL] [Abstract][Full Text] [Related]
12. Treatment of bone pain secondary to metastases using samarium-153-EDTMP.
Etchebehere EC; Pereira Neto CA; Lima MC; Santos Ade O; Ramos CD; Silva CM; Camargo EE
Sao Paulo Med J; 2004 Sep; 122(5):208-12. PubMed ID: 15558143
[TBL] [Abstract][Full Text] [Related]
13. Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
Turner JH; Martindale AA; Sorby P; Hetherington EL; Fleay RF; Hoffman RF; Claringbold PG
Eur J Nucl Med; 1989; 15(12):784-95. PubMed ID: 2483138
[TBL] [Abstract][Full Text] [Related]
14. [Primary investigation of dose-effect relationship of 153Sm-EDTMP in treating multiple bone metastases].
Fan W; Chen LX; Liu XW; Tang Q; Wang GH; Zhi SF; Zeng ZY
Ai Zheng; 2006 Nov; 25(11):1395-8. PubMed ID: 17094908
[TBL] [Abstract][Full Text] [Related]
15. Optimal treatment of painful bone metastases with Samarium EDTMP in a haemodialysis patient: effectiveness and safety of internal radiotherapy.
Skalli S; Desruet MD; Bourre JC; Caravel JP; Vuillez JP
Nephrol Dial Transplant; 2009 Aug; 24(8):2598-600. PubMed ID: 19369693
[TBL] [Abstract][Full Text] [Related]
16. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
[TBL] [Abstract][Full Text] [Related]
17. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma.
Franzius C; Bielack S; Flege S; Eckardt J; Sciuk J; Jürgens H; Schober O
Nuklearmedizin; 2001 Dec; 40(6):215-20. PubMed ID: 11797510
[TBL] [Abstract][Full Text] [Related]
18. Samarium 153Sm lexidronam.
Lamb HM; Faulds D
Drugs Aging; 1997 Nov; 11(5):413-8; discussion 419. PubMed ID: 9359026
[TBL] [Abstract][Full Text] [Related]
19. Use of samarium Sm 153 lexidronam for the treatment of dogs with primary tumors of the skull: 20 cases (1986-2006).
Vancil JM; Henry CJ; Milner RJ; McCoig AM; Lattimer JC; Villamil JA; McCaw DL; Bryan JN
J Am Vet Med Assoc; 2012 Jun; 240(11):1310-5. PubMed ID: 22607597
[TBL] [Abstract][Full Text] [Related]
20. Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach.
Bruland OS; Skretting A; Solheim OP; Aas M
Acta Oncol; 1996; 35(3):381-4. PubMed ID: 8679270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
